Page 60 - Strategies for non-invasive managementof high-grade cervical intraepithelial neoplasia - prognostic biomarkers and immunotherapy Margot Maria Koeneman

Chapter 2
28. Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nature reviews Cancer. 2010;10(8):550-60.
* this review provides an excellent overview of HPV induced molecular mechanisms leading to cervical cancer
29. Doorbar J, Quint W, Banks L, et al. The biology and life-cycle of human papillomaviruses. Vaccine. 2012;30 Suppl 5:F55-70.
** this review provides an excellent overview of HPV biology, life cycle and HPV oncogenic properties
30. Herfs M, Somja J, Howitt BE, et al. Unique recurrence patterns of cervical intraepithelial neoplasia after excision of the squamocolumnar junction. International journal of cancer. 2015 Mar 1;136(5): 1043-52.
31. Wentzensen N, von Knebel Doeberitz M. Biomarkers in cervical cancer screening. Disease markers. 2007;23(4):315-30.
32. Jimenez-Wences H, Peralta-Zaragoza O, Fernandez-Tilapa G. Human papilloma virus, DNA methylation and microRNA expression in cervical cancer (Review). Oncology reports. 2014;31(6):2467-76.
33. Clarke MA, Wentzensen N, Mirabello L, et al. Human papillomavirus DNA methylation as a potential biomarker for cervical cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2012;21(12):2125-37.
34. Stanley MA. Epithelial cell responses to infection with human papillomavirus. Clinical microbiology reviews. 2012;25(2):215-22.
* this review provides an excellent overview of the host immune response to HPV infection and HPV immune evasion strategies
35. Patel S, Chiplunkar S. Host immune responses to cervical cancer. Current opinion in obstetrics & gynecology. 2009;21(1):54-9.
* this review provides an excellent overview of the host immune response to HPV infection and HPV immune evasion strategies
36. Maglennon GA, Doorbar J. The biology of papillomavirus latency. The open virology journal. 2012;6:190-7.
37. Bais AG, Beckmann I, Lindemans J, et al. A shift to a peripheral Th2-type cytokine pattern during the carcinogenesis of cervical cancer becomes manifest in CIN III lesions. Journal of clinical pathology. 2005;58(10):1096-100.
38. Sharma A, Rajappa M, Saxena A, Sharma M. Cytokine profile in Indian women with cervical intraepithelial neoplasia and cancer cervix. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2007;17(4):879-85.
39. Visser J, Nijman HW, Hoogenboom BN, et al. Frequencies and role of regulatory T cells in patients with (pre)malignant cervical neoplasia. Clinical and experimental immunology. 2007;150(2):199-209.
40. Doorbar J. Papillomavirus life cycle organization and biomarker selection. Disease markers. 2007;23(4):297-313.
41. de Freitas AC, Coimbra EC, Leitao MD. Molecular targets of HPV oncoproteins: Potential biomarkers for cervical carcinogenesis. Biochimica et biophysica acta. 2014;1845(2):91-103.
58